Associated Papers
Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers.
Mori T et al.
Cancer Medicine, 2023
36345163 (PubMed )
Supplement: CAM4-12-6594-s002.xlsx › Supp_Table1
Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2.
Aljarf R et al.
Scientific Reports, 2022
35729312 (PubMed )
Supplement: 41598_2022_13508_MOESM2_ESM.xlsx › Sheet1
Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
ElBiad O et al.
Bmc Cancer, 2022
Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
Bhaskaran SP et al.
International Journal of Cancer, 2019
30702160 (PubMed )
Supplement: IJC-145-962-s004.xlsx › BRCA1
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Yoshida R et al.
Oncotarget, 2019
Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
Arai M et al.
Journal of Human Genetics, 2018
Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Kim YC et al.
Oncotarget, 2016
26848529 (PubMed )
Supplement: oncotarget-07-9600-s002.xlsx › Sheet1
Familial breast and ovarian cancers.
Arai M et al.
International Journal of Clinical Oncology, 2004
Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.
Liede A et al.
Human Mutation, 2002
Select a paper to view details